HOME >> BIOLOGY >> NEWS
Proteins may help identify patients who will respond better to treatments in certain cancers

Scientists today presented studies of proteomic and genomic markers that could help oncologists devise better treatment approaches for specific patients, and may improve clinical outcomes. The studies were presented here today at the International Conference on Molecular Targets and Cancer Therapeutics organized by the American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC).

Molecular marker expression phenotype is an independent prognostic factor for outcome in the chart head and neck cancer randomized trial: Abstract 733

A clinical study of head and neck cancer patients found that molecular markers -- the proteins that distinguish specific tumors -- allowed doctors to identify patients who would respond better to radiotherapy than others. Investigators looked at molecular marker expression profiles in 402 patients with head and neck squamous cell carcinoma. The study focused on biological factors such as vascular density and the expression of proteins involved in the regulation of cell cycle progression, proliferation, or apoptosis (programmed cell death), which are known to affect the way that a tumor responds to radiotherapy.

"We are using new strategies for data analysis to exploit the potential of molecular markers," said Francesca Buffa, PhD, of the Gray Cancer Institute in London. "We hope that by tailoring cancer therapy to the biological behavior of an individual patient's tumor, we will be able to improve the success of radiotherapy and provide increased clinical benefits to the patients," she added.

Eight distinct groups of tumors, each with similar biological profiles, were identified within the patient group. Drs. Buffa, Soren Bentzen and their colleagues looked at whether it was possible to predict the outcome of radiotherapy based on these molecular profiles, when compared to more traditional characteristics such as t
'"/>

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
19-Nov-2003


Page: 1 2 3

Related biology news :

1. Proteins show promise for mosquito control
2. Proteins transform DNA into molecular velcro
3. Proteins enable HIV to override cells defenses
4. New Science Press launches Proteins: From Sequence to Structure
5. Report: Proteins can be engineered as widely adaptable bioelectronic sensors
6. Proteins in African HIV strains interact differently with drugs
7. Proteins are vastly more complicated than previously realized
8. Life and death struggle: Proteins play against each other, bringing balance to immune system
9. Proteins that bind to sperm offer clues to male fertility and possible male contraception
10. Scientists Show Proteins Function Individually As Part Of DNA Repair
11. Genes Found That Label Cell Proteins For Disposal

Post Your Comments:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: